SGR-1505 Clinical Progress and Program Update During Pipeline Day, Schrödinger is presenting new data showing that its novel MALT1 inhibitor, SGR-1505, was well tolerated in a Phase 1 study of 73 ...

Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.

Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data ...

SGR-3515 Data at ENA 2024 The presentation (Abstract # 147), “Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated pharmacological properties in xenograft tumor models ...

Schrodinger (SDGR) announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium. The data demonstrate that in ...

NEW YORK, October 23, 2024--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI ...